Tikkanen I - Search Results

1

Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.

Tikkanen I, Tikkanen T, Cao Z, Allen TJ, Davis BJ, Lassila M, Casley D, Johnston CI, Burrell LM, Cooper ME. Tikkanen I, et al. Among authors: tikkanen t. J Hypertens. 2002 Apr;20(4):707-14. doi: 10.1097/00004872-200204000-00029. J Hypertens. 2002. PMID: 11910307

2

Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.

Tikkanen T, Tikkanen I, Rockell MD, Allen TJ, Johnston CI, Cooper ME, Burrell LM. Tikkanen T, et al. Among authors: tikkanen i. Hypertension. 1998 Oct;32(4):778-85. doi: 10.1161/01.hyp.32.4.778. Hypertension. 1998. PMID: 9774379

3

Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats.

Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE. Cao Z, et al. Among authors: tikkanen i. Kidney Int. 2001 Aug;60(2):715-21. doi: 10.1046/j.1523-1755.2001.060002715.x. Kidney Int. 2001. PMID: 11473654 Free article.

4

Comparison of renin-angiotensin to calcium channel blockade in renal disease.

Tikkanen I, Johnston CI. Tikkanen I, et al. Kidney Int Suppl. 1997 Dec;63:S19-22. Kidney Int Suppl. 1997. PMID: 9407414 Review.

5

Mechanism of progression of renal disease: current hemodynamic concepts.

Johnston CI, Risvanis J, Naitoh M, Tikkanen I. Johnston CI, et al. Among authors: tikkanen i. J Hypertens Suppl. 1998 Sep;16(4):S3-7. J Hypertens Suppl. 1998. PMID: 9817185 Review.

6

[Angiotensin II antagonists].

Tikkanen I, Tikkanen T. Tikkanen I, et al. Among authors: tikkanen t. Duodecim. 1995;111(18):1733-5. Duodecim. 1995. PMID: 9340266 Finnish. No abstract available.

7

Prolonged neutral endopeptidase inhibition in heart failure.

Helin K, Tikkanen I, Tikkanen T, Saijonmaa O, Sybertz EJ, Vemulapalli S, Sariola H, Fyhrquist F. Helin K, et al. Among authors: tikkanen i, tikkanen t. Eur J Pharmacol. 1991 May 30;198(1):23-30. doi: 10.1016/0014-2999(91)90557-7. Eur J Pharmacol. 1991. PMID: 1655477

8

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.

Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, Broedl UC, Lund SS. Cherney DZI, et al. Among authors: tikkanen i. Kidney Int. 2018 Jan;93(1):231-244. doi: 10.1016/j.kint.2017.06.017. Epub 2017 Aug 30. Kidney Int. 2018. PMID: 28860019 Free article.

9

Plasma atrial natriuretic peptide in DOCA-NaCl-treated rats.

Tikkanen T, Tikkanen I, Fyhrquist F. Tikkanen T, et al. Among authors: tikkanen i. Acta Physiol Scand. 1987 Feb;129(2):151-5. doi: 10.1111/j.1748-1716.1987.tb08053.x. Acta Physiol Scand. 1987. PMID: 2953170

10

Screening for renovascular hypertension in a population with relatively low prevalence.

Helin KH, Tikkanen I, von Knorring JE, Lepäntalo MJ, Liewendahl BK, Laasonen LS, Fyhrquist FY, Tikkanen T. Helin KH, et al. Among authors: tikkanen i, tikkanen t. J Hypertens. 1998 Oct;16(10):1523-9. doi: 10.1097/00004872-199816100-00018. J Hypertens. 1998. PMID: 9814625

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

216 results

Search Page

Filters